Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Treatment Results of Radical Radiotherapy in Uterine Cervix Cancer

자궁경부암 환자의 근치적 방사선치료성적

  • Huh Seung Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim Bo Kyong (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim Do Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Shin Seong Soo (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee Jeong Eun (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang Min Kyu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn Yong Chan (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 허승재 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 김보경 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 임도훈 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 신성수 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 이정은 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 강민규 (성균관대학교 의과대학 삼성서울병원 치료방사선과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 치료방사선과)
  • Published : 2002.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study was conducted to evaluate the treatment results, prognostic factors, and complication rates after high dose rate (HDR) brachytherapy in patients with uterine cervix cancer who were treated with curative aim. Materials and Methods : Of 269 cervix cancer patients treated at the department of radiation oncology, Samsung Medical Center from September 1994 to July 1998, the 106 who were treated with radical radio-therapy were analyzed. The median age was 61 years (range 22 to 89). All patients except 4 with carcinoma in situ (CIS) were given external beam radiotherapy (range $30.6\~50.4\;Gy$ to whole pelvis) and HDR brachytherapy. The common regimens of HDR brachytherapy were a total dose of $24\~28\;Gy$ with $6\~7$ fractions to point A at two fractions per week. The median overall treatment time was 55 days (range 44 to 104) in patients given both external beam radiotherapy and HDR brachytherapy. Results : Early responses of radiotherapy were evaluated by gynecologic examination and follow-up MRI 1 month after radiotherapy. Treatment responses were complete remission in 72 patients, partial response in 33 and no response in 1. The overall survival (OS) rate of all patients was $82\%,\;and\;73\%$, and the disease free survival (DFS) rate was $72\%,\;and\;69\%$, at 3, and 5 years, respectively. The pelvic control rate (PCR) was $79\%$ at both 3 and 5 years. According to the FIGO stage,3 and 5 year OS were $100\%\;and\;50\%$ in CIS/IA, $100\%\;and\;100%$ in IB, $83\%\;and\;69\%$ in IIA, $87\%\;and\;80\%$ in IIB, and $62\%\;and\;62\%$ in III, respectively. The 3 year OS in 4 patients with stage IVA was $100\%$. Three-year DFS were $80\%$ in CIS/IA, $88\%$ in IB, $100\%$ in IIA, $64\%$ in IIB, $58\%$ in III, and $75\%$ in IVA. Three-year PCR were $100\%$ in CIS/IA, $94\%$ in IB, $100\%$ in IIA, $84\%$ in IIB, $69\%$ in III, and $50\%$ in IVA. By univariate analysis, FIGO stage and treatment response were significant factors for OS. The significant factors for DFS were age, FIGO stage, treatment response and overall treatment time (OTT). For pelvic control rate, treatment response and OTT were significant factors. By multivariate analysis, FIGO stage had a borderline significance for OS (p=0.0825) and treatment response had a borderline significance for DFS (0=0.0872). A total of 14 patients $(13\%)$ experienced rectal bleeding, which occurred from 3 to 44 months (median, 13 months) after the completion of radiotherapy. Conclusion : HDR brachytherapy protocol of Samsung Medical Center combined with properly optimal external beam pelvic irradiation is a safe and effective treatment for patients with uterine cervix cancer. The authors found that OTT of less than 55 days had a positive impact on pelvic control and survival rate.

목적 : 삼성서울병원 치료방사선과에서 근치적 목적으로 외부조사와 고선량율 강내치료를 이용하여 치료한 자궁경부암 환자의 치료 성적을 분석하고자 하였다. 대상 및 방법 : 1994년 9월부터 1998년 7월까지 근치적 목적으로 방사선치료를 시행한 106명의 환자를 대상으로 분석하였으며, 환자의 연령분포는 $22\~89$세(중앙값, 61세)이었다. 98명의 환자에서 편평상피암이었다. 환자의 FIGO 병기는 CIS 4명, IA 4명, IB 17명, IIA 15명, IIB 33명, IIIA 2명, IIIB 27명, IVA가 4명이었다. ECOG 활동도는 88명에서 1이하였다. 11명의 환자에서 전보조화학요법이 시행되었다. 방사선치료는 상피내암인 4명을 제외한 102명에서 30.6-50.4 Gy를 외부 조사하였으며 고선량율 강내치료를 모든 환자에서 A점 기준으로 24 Gy/6회 시행하였다. 치료 예후 인자는 연령($\leq60$세 vs >60세), 병리조직학적 소견(편평상피암 vs 기타 병리), FIGO 병기(IIA 이하 vs IIB vs IIIA 이상), ECOG 활동도(ECOG 0, 1 vs 2), 항암화학요법의 시행여부, 그리고 방사선치료 후 반응정도(완전관해 vs 부분관해), 방사선치료기간($\leq55$일 vs >55일)에 따라 비교하였다. 환자의 추적관찰기간은 $6\~66$개월(중앙값, 28개월)이었다. 결과 : 전체 3년 및 5년 생존율은 각각 $82\%,\;73\%$이었으며, 무병생존율은 각각 $72\%,\;69\%$이었다. FIGO 병기별 생존율은 병기 IB, IIA, IIB, 그리고 III에서 3년 생존율이 각각 $100\%,\;83\%,\;87\%,\;62\%$이었고 5년 생존율은 IB $100\%$, IIA $69\%$, IIB $80\%$, III에서는 $62\%$이었다. 단변량분석에 따른 예후인자를 살펴보면 전체생존율에서는 FIGO 병기와 방사선치료의 반응이 무병생존율과 골반부 조절율에는 나이와 병기, 방사선치료의 반응, 방사선치료기간이 의미 있는 인자로 확인되었다. 방사선치료 부작용으로 직장 출혈은 모두 14명$(13\%)$의 환자에서 나타났다. 결론 : 자궁경부암 환자의 고선량율 강내치료와 외부 방사선치료는 효과적인 치료방법임을 확인하였으며, 치료기간의 단축이 중요한 예후 결정 요인임을 확인할 수 있었다.

Keywords

References

  1. Cancer PrevaIence Statistics. 21th Korean Central Central Cancer Registry Report., National Cancer Center, 2001
  2. Coia L, Won M, Lanciano R, et aI. The patterns of care outcome study for cancer of the uterine cervix : Results of the secome study for cancer of the uterine cervix : Results of the second national practice survey. Cancer 1990;66:2451-2456 https://doi.org/10.1002/1097-0142(19901215)66:12<2451::AID-CNCR2820661202>3.0.CO;2-5
  3. Perez CA, Breaux S, Madoc-Jones H, et aI. Radiation therapy alone in the treatment of carcinoma of uterine cervix: Analysis of tumor recurrence. Cancer 1983;54:1393-1402
  4. Montana GS, FowIer WC, Varra MA, et aI. Carcinoma of the cervix, stage lll : Results of radiation therapy. Cancer 1986;57:148-154 https://doi.org/10.1002/1097-0142(19860101)57:1<148::AID-CNCR2820570130>3.0.CO;2-7
  5. Lanciano RM, Won M, Coia LR, et aI. Pretreatment and treatment factors associated with improved outcome in spuamous cell carcinoma of the uterine cervix cancer : A final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys 1991;20:667-676 https://doi.org/10.1016/0360-3016(91)90007-Q
  6. EifeI PJ, Morris M, OswaId MJ. The influence of tumor size and growth habit on outcome of patients with FIGO stage IB spuamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1993;27:127-128
  7. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48:201-211 https://doi.org/10.1016/S0360-3016(00)00497-1
  8. Huh SJ, Ahn YC, Choi DR, et aI. Current status of high dose rate brachytherapy for uterine cervix cancer in Korea. The Journal of JASTRO 1996;8;277-281
  9. Huh SJ. Current status of high dose rate brachytherapy in cervical cancer in Korea and optimal treatment schedule. J Korean Soc Ther Radiol Oncol 1998;16:357-366
  10. Huh SJ, Lim DH, Ahn YC, et aI. Effect of customized small bowel displacement system in pelvic irradiation. Int J Radiat Oncol Biol Phys 1998;40:623-627 https://doi.org/10.1016/S0360-3016(97)00764-5
  11. Chassagne D, Sismondi P, Horiot JC et aI. A glossary for reporting complications of treatment in gynecological cancers Radiother Oncol 1993;26:195-202
  12. International Commission on Radiation Units and Measurements Report 38, Dose and Volume Specifications for Reporting Intracavitary Therapy in Gynecology. International Commission on Radiation Units and Meacurements. Bethesda, MD, 1985
  13. Suh CO, Kim KE, Loh JK, et aI. Treatment of carcinoma of the uterine cervix with high dose rate intracavitary irradiation using Ralstron. The Journal of the Korean Society of Therapeutic Radiology 1990;8:231-240
  14. Lee SW, Suh CO, Chung EJ, Kim GE. Dose optimization of fractionated external radiation and high-dose-rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncos Biol Phys 2002;52:1338-1344 https://doi.org/10.1016/S0360-3016(01)02821-8
  15. Huh SJ. The result of curative radiotherapy for carcinoma of uterine cervix. The Journal of the Korean Society of Therapeutic Radiology 1993;11:143-149
  16. Moon CW, Jeung TS, Yum, HY. Analysis of radiotherapy associated factors in stage IIb carcinoma of uterine cervix. The Journal of the Korean Society of Therapeutic Radiology 1990;8:241-254
  17. Kim OB, Choi TJ, Kim JH, et aI. Carcinoma of uterine cervix treated with high dose rate intracavitary irradiation : pattern of failue. The Journasl of the Korean Society of Therapeutic Radiology 1993;11:369-376
  18. KiI WJ., Chun M, Kang S, et aI. Radiotherapy results in stage IIB uterine cervix cervix cancer. J Korean Soc Ther Radiol Oncol 2001;19:345-352
  19. Shigematsu Y, Nishiyama K, Masaki N, et aI. Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitaty radiotherapy with high dose rate-acomparative study with low dose rate system. Int J Radiat Oncol Biol Phys 1983;9:351-356
  20. Orton CG, Seyedasdr M, Somnay A. Comparison of high and low Dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 1991;21:1425-1434 https://doi.org/10.1016/0360-3016(91)90316-V
  21. EifeI PJ. High dose rate brachytherapy for carcinoma of the cervix: High tech or high risk? Int J Radiat Oncol Biol Phys 1996;24:383
  22. Okawa T, Sakada S, Kita-Okawa M, et aI. Comparison between high dose rate and low dose rate brachytherapy for cervical cancer : Japanese experienoe with treatment and complications(1975-1985). The Journal of JASTRO 1996;8:135-142
  23. Souhami L, Seymour R, Roman TN et aI. Weekly cisplstin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oneol Biol Phys 1993;27:871-878 https://doi.org/10.1016/0360-3016(93)90462-5
  24. Shin KH, Huh SJ, Chie EK, et aI. Analysis of correlation between rectal complications and rectal dose following high dose rate intracavitary radiotherapy in patients with uterine cervix cancer : in vivo dosimetric analysis. Radiation Medicine 1999;17:289-293
  25. Lim, DH, Huh SJ, Shin KH, Ahn YC, Kim DY. In Vivo dosimetric analysis between rectal dose and rectao complication in patients with cerrvix cancer treated with high dose rate intracavitary radiotherapy. Int J Radiat Oncol Biol Phys 2001(S1);51:329-330
  26. Kapp KS, StueckIschweiger GF, Kapp DS, et aI. Carcinoma of the cervix: analysis of compIications after primary external beam radiation and Ir-192 HDR brachytherapy. Radiother Oncol 1997;42:143-153 https://doi.org/10.1016/S0167-8140(96)01881-6
  27. Huh SJ, Kim B, Shin SS, et aI. Pelvic insufficiency fracture after pelvic irradiation in uterine cervix cancer. J Korean Soc Ther Radiol Oncol 2001;19(S):48
  28. Huh SJ, Kim BK, Kang MK, et aI. Pelvic Insufficiency Fracture after Pelvic Irradiation in Uterine Cervix Cancer. Gynecol Oncol 2002;86:264-268 https://doi.org/10.1006/gyno.2002.6756
  29. Hsu WL, Wu CJ, Jen TM, et aI. Twice-a-day fractionated high vs. continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer : A nonrandomized comparison of treatment results. Int JRadiat Oncol Biol Phys 1995;32:1425-1431
  30. Arai T, Nakano T, Morita S, et aI. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix : A 20-year experience. Cancer 1992;69:175-180 https://doi.org/10.1002/1097-0142(19920101)69:1<175::AID-CNCR2820690129>3.0.CO;2-B
  31. Arai T, Nakano T, Morita S, et aI. Longterm treatment result of radiotherapy for cervical spuamous cell cancer. The Journal of JASTRO 1997; 9:146(abst)
  32. Akine Y, Tokita N, Ongino T, et aI. Dose epuivalence for high dose rate to low dose rate intracavitary irradiation in the treatment of cancer of uterine cervix. Int J Radiat Oncol Biol Phys 1990;19:1511-1514 https://doi.org/10.1016/0360-3016(90)90365-Q
  33. Chatani M, Matayoshi Y, Masaki N, Inoue T. High dose rate intracavitary irradiation for carcinoma of the uterine cervix cancer. The adverse effect of treatment prolongation. Strahlenther Onkol 1997;173:379-384
  34. Petereit DG, Sarkaria JN, ChappeII R, et aI The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 1995;32:1301-1307
  35. DeIaIoye JF, Coucke PA, PampaIIona S, PeItecu G, De Grandi P. Radiation therapy duration influences overall survival in patients with cervical carcinoma. Int J Gynecol Obstet 1997;57:295-303 https://doi.org/10.1016/S0020-7292(97)02888-9
  36. Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for spuamous cell cancer of the uterine cervix treated with radion : a pattertns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391-397 https://doi.org/10.1016/0360-3016(93)90058-4
  37. EifeI PJ, Moughan J, Owen J, Katz A, Mahon I, Hanks GE. Patterns of radiotherapy practice for patients with spuamous carcinoma of the uterine cervix : patterns of care atudy. Int J Radiat Oncol Biol Phys 1999;43:351-358 https://doi.org/10.1016/S0360-3016(98)00401-5
  38. Lehman M, Thomas G. Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer? Int J Gynecol Cancer 2001;11:87-99
  39. NCI. Concurrent chemoradiation for cervical cancer. February 22. 1999 Washington D.C
  40. Potter, R, Knocke TH. The potential of 3-D conformal brachytherapy and external beam radiotherapy in cervix cancer. StrahIenther Onkol 2001;177:641-642 https://doi.org/10.1007/PL00002377
  41. Pearcy R, Brundage M, Drouin P, et aI. Phase III trial comparing radical radiotherapy with and without cispIatin chemotherapy in patients with advanced spuamous ceII cancer of the cervix. J CncoI 2002;20:966-972